Opara Józef, Hordyńska Ewa, Swoboda Anna
Katedra Fizjoterapii Układu Nerwowego i Narzadu Ruchu AWF, Katowice.
Ortop Traumatol Rehabil. 2007 May-Jun;9(3):277-85.
Botulinum toxin (BTX is currently a recognised treatment for local spasticity, especially in children with cerebral palsy. The following paper presents the early result of BTX treatment for adult patients with spastic paresis of the lower limbs.
Twenty adult paraplegic patients (mean age 42 years) following cervical or thoracic SCI or suffering from MS, with moderate-to-severe spasticity in the lower extremities received BTX for the first time in life into the thigh adductor, knee flexor and foot flexor muscle groups. Results were evaluated using Modified Ashworth's Scale, Visual (Analogue) Scale for Pain Assessment, Modified Rivermead Mobility Index and Repty Functional Index prior to and three weeks after the administration of the toxin.
Improvement was observed in most patients, usually manifesting as reductions or resolution of pain. Mild side effects (low-grade fever and flu-like symptoms) occurred in only one patient.
Our study confirmed the efficacy and safety of BTX for focal lower limb spasticity in adults.
肉毒杆菌毒素(BTX)目前是公认的治疗局部痉挛的方法,尤其适用于脑瘫患儿。以下论文介绍了BTX治疗成年下肢痉挛性轻瘫患者的早期结果。
20例成年截瘫患者(平均年龄42岁),因颈髓或胸髓损伤或患有多发性硬化症,下肢有中度至重度痉挛,首次接受BTX注射至大腿内收肌、屈膝肌和足部屈肌肌群。在注射毒素前及注射后三周,使用改良Ashworth量表、视觉(模拟)疼痛评估量表、改良Rivermead运动指数和Repty功能指数对结果进行评估。
大多数患者病情有改善,通常表现为疼痛减轻或消失。仅1例患者出现轻微副作用(低热和类似流感的症状)。
我们的研究证实了BTX治疗成人局灶性下肢痉挛的有效性和安全性。